Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy

The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single drug therapy. Reprogramming of the RTK network leading to alteration in RTK co-expression in response to drug intervention is a dynamic mechanism of acquired resistance to single drug therapy in many cancers. One route to overcome this resistance is combination therapy. We describe the results of a joint in silico, in vitro, and in vivo investigations on the efficacy of trastuzumab, pertuzumab and their combination to target the HER2 receptors. Computational modelling revealed that these two drugs alone and in combination differentially suppressed RTK network activation depending on RTK co-expression. Analyses of mRNA expression in SKOV3 ovarian tumour xenograft showed up-regulation of HER3 following treatment. Considering this in a computational model revealed that HER3 up-regulation reprograms RTK kinetics from HER2 homodimerisation to HER3/HER2 heterodimerisation. The results showed synergy of the trastuzumab and pertuzumab combination treatment of the HER2 overexpressing tumour can be due to an independence of the combination effect on HER3/HER2 composition when it changes due to drug-induced RTK reprogramming.

[1]  N. Zaffaroni,et al.  Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells. , 2014, Cancer letters.

[2]  A. Yu,et al.  FOXO1-dependent DNA damage repair is regulated by JNK in lung cancer cells. , 2014, International journal of oncology.

[3]  Simon P. Langdon,et al.  Customizing the Therapeutic Response of Signaling Networks to Promote Antitumor Responses by Drug Combinations , 2014, Front. Oncol..

[4]  T. Kallunki,et al.  When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase , 2014, Cells.

[5]  S. Collins,et al.  Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. , 2013, Cancer research.

[6]  Michael L. Gatza,et al.  FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. , 2013, Cancer research.

[7]  P. Lønning,et al.  Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue , 2013, PloS one.

[8]  Yi Zhang,et al.  Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3 , 2013, PLoS Comput. Biol..

[9]  M. Schlissel,et al.  MK5 activates Rag transcription via Foxo1 in developing B cells , 2013, The Journal of experimental medicine.

[10]  J. T. Jørgensen,et al.  Companion Diagnostics in Oncology - Current Status and Future Aspects , 2013, Oncology.

[11]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[12]  A. Viale,et al.  Relief of Feedback Inhibition of Her3 Transcription by Raf and Mek Inhibitors Attenuates Their Antitumor Effects in Braf -mutant Thyroid Carcinomas Human Oncology and Pathogenesis Program, Pathology, And , 2022 .

[13]  T. Yap,et al.  Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Paul S Mischel,et al.  A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. , 2013, Carcinogenesis.

[15]  Michael Q. Zhang,et al.  Novel Foxo 1 – dependent transcriptional programs control T reg cell function , 2013 .

[16]  J. Bown,et al.  Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer. , 2013, Cellular signalling.

[17]  C. Arteaga,et al.  Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function , 2012, Clinical Cancer Research.

[18]  B. Hennessy,et al.  Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. , 2012 .

[19]  B. Hennessy,et al.  Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Haiyan Xu,et al.  Mapping MKP-3/FOXO1 Interaction and Evaluating the Effect on Gluconeogenesis , 2012, PloS one.

[21]  Igor Goryanin,et al.  Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  D. Harrison,et al.  Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer , 2012, British Journal of Cancer.

[23]  B. Kholodenko,et al.  Computational Approaches for Analyzing Information Flow in Biological Networks , 2012, Science Signaling.

[24]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[25]  David J Harrison,et al.  Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. , 2012, Cellular signalling.

[26]  B. van Deurs,et al.  EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. , 2012, Cellular signalling.

[27]  Naimei Tang,et al.  Akt, FoxO and regulation of apoptosis. , 2011, Biochimica et biophysica acta.

[28]  G. Tzivion,et al.  FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. , 2011, Biochimica et biophysica acta.

[29]  Holger Conzelmann,et al.  Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. , 2011, Molecular cell.

[30]  Huizhong Hu.  HER receptor-mediated dynamic signalling in breast cancer cells , 2011 .

[31]  K. Furugaki,et al.  Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models , 2011, Clinical Cancer Research.

[32]  J. Baselga,et al.  Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism , 2011, Breast Cancer Research.

[33]  D. Harrison,et al.  Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies , 2011, Clinical Cancer Research.

[34]  William Pao,et al.  Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase , 2011, Proceedings of the National Academy of Sciences.

[35]  G. Mills,et al.  Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. , 2011, Cancer research.

[36]  Carlos L. Arteaga,et al.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.

[37]  Igor Goryanin,et al.  Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition. , 2011, Cellular signalling.

[38]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[39]  Sharmila Shankar,et al.  Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer , 2010, Journal of molecular signaling.

[40]  D. Lauffenburger,et al.  Structure of the EGF receptor transactivation circuit integrates multiple signals with cell context. , 2010, Molecular bioSystems.

[41]  A. Xu,et al.  Receptor tyrosine kinase coactivation networks in cancer. , 2010, Cancer research.

[42]  N. Maihle,et al.  Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics , 2010, Journal of ovarian research.

[43]  W. Hahn,et al.  Protein Phosphatase 2A Reactivates FOXO3a through a Dynamic Interplay with 14-3-3 and AKT , 2010, Molecular biology of the cell.

[44]  Werner Scheuer,et al.  Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. , 2009, Cancer research.

[45]  Haluk Resat,et al.  Bmc Cell Biology Her/erbb Receptor Interactions and Signaling Patterns in Human Mammary Epithelial Cells , 2009 .

[46]  D. Harrison,et al.  Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity , 2009, Molecular Cancer Research.

[47]  Igor Goryanin,et al.  Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. , 2009, Cancer research.

[48]  Steffen Klamt,et al.  The Logic of EGFR/ErbB Signaling: Theoretical Properties and Analysis of High-Throughput Data , 2009, PLoS Comput. Biol..

[49]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[50]  J. Baselga,et al.  Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[52]  Andre T Baron,et al.  Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. , 2009, Cancer research.

[53]  C. Ries,et al.  Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab , 2009, Oncogene.

[54]  D. Lauffenburger,et al.  Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data , 2009, Molecular systems biology.

[55]  T. Aigner,et al.  FOXO3a: a novel player in thyroid carcinogenesis? , 2008, Endocrine-related cancer.

[56]  M. Sliwkowski,et al.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. , 2008, Cancer research.

[57]  D. Tindall,et al.  FOXOs, cancer and regulation of apoptosis , 2008, Oncogene.

[58]  Arndt Hartmann,et al.  Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients , 2008, Breast Cancer Research.

[59]  N. Sergina,et al.  The HER family and cancer: emerging molecular mechanisms and therapeutic targets. , 2007, Trends in molecular medicine.

[60]  B. Kholodenko,et al.  Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses , 2007, Molecular systems biology.

[61]  Erez M. Bublil,et al.  The EGF receptor family : spearheading a merger of signaling and therapeutics , 2007 .

[62]  R. Landgraf,et al.  HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks , 2007, Breast Cancer Research.

[63]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[64]  Haluk Resat,et al.  Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. , 2006, Biophysical journal.

[65]  L. Presta,et al.  Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab , 2006, Cancer Immunology, Immunotherapy.

[66]  M. Mann,et al.  Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.

[67]  N. Normanno,et al.  The ErbB receptors and their ligands in cancer: an overview. , 2005, Current drug targets.

[68]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[69]  M. Sliwkowski,et al.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.

[70]  G. Sonenshein,et al.  Forkhead Box Transcription Factor FOXO3a Regulates Estrogen Receptor Alpha Expression and Is Repressed by the Her-2/neu/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway , 2004, Molecular and Cellular Biology.

[71]  H. Burris,et al.  Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. , 2004, The oncologist.

[72]  Richard D. Byrne,et al.  Bisperoxovanadium compounds are potent PTEN inhibitors , 2004, FEBS letters.

[73]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[74]  N. Hynes,et al.  ErbB receptors: directing key signaling networks throughout life. , 2004, Annual review of pharmacology and toxicology.

[75]  Kuo-Fen Lee,et al.  Essential roles of Her2/erbB2 in cardiac development and function. , 2004, Recent progress in hormone research.

[76]  S. Kimura,et al.  A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. , 2003, The Biochemical journal.

[77]  X. Cui,et al.  Statistical tests for differential expression in cDNA microarray experiments , 2003, Genome Biology.

[78]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[79]  Brian Higgins,et al.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.

[80]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[81]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[82]  A. Lenferink,et al.  Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.

[83]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[84]  B. Kholodenko,et al.  Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor* , 1999, The Journal of Biological Chemistry.

[85]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[86]  Y. Yarden,et al.  The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.

[87]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[88]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[89]  Supplemental Information 2: Kyoto Encyclopedia of genes and genomes. , 2022 .